D-Gam Human Anti-D Immunoglobulin 1 500 Iu And 2 500 Iu Solution For Injection
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
D-GAM ®, Human Anti-D Immunoglobulin, 1,500 and 2,500 IU, solution for injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains either 1500 IU or 2500 IU human Anti-D immunoglobulin
One ml contains 1250 IU/mL human Anti-D immunoglobulin.
*100 micrograms of human anti-D immunoglobulin correspond to 500 international units (IU).
Human protein content 20 - 180 g/L of which at least 95% is IgG.
For excipients see 6.1.
3 PHARMACEUTICAL FORM
A solution for injection.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Prevention of RhD immunisation in RhD negative women:
i. Pregnancy/delivery of a RhD positive baby.
ii. Abortion/threatened abortion, ectopic pregnancy or hydatidiform mole.
iii. After ante-partum haemorrhage (APH), amniocentesis, chorionic biopsy or obstetric manipulative procedure e.g. external version, or abdominal trauma, which may cause transplacental haemorrhage (TPH).
Treatment of RhD negative patients after transfusions of RhD positive blood or other products containing RhD positive red blood cells (e.g. platelets).
4.2 Posology and method of administration
Posology
a) Post-Natal Dosage:
The recommended dose is 500 IU.
For postnatal use, the product should be administered as soon as possible within 72 hours of delivery.
If a large fetomaternal haemorrhage is suspected, its extent should be determined by a suitable method and additional doses of anti-D should be administered as indicated.
b) Ante-Natal Prophylaxis:
A single dose of 1,500 IU at 28 weeks of gestation, or 500 IU given at both 28 and 34 weeks of gestation.
c) Following a Potentially Sensitising Event During Pregnancy:
D-GAM ® should be administered as soon as possible and no later than 72 hours after the event.
Up to 20 weeks gestation: recommended dose is 250 IU per incident.
After 20 weeks gestation: recommended dose is 500 IU per incident. A test for the size of the FMH should be performed when anti-D is given after 20 weeks and additional doses of anti-D should be administered as indicated.
d) Prevention of Immunisation in RhD Negative Patients Given Blood Components Containing RhD Positive Cells:
Recommended doses: 125 IU per mL of transfused RhD positive red cells; 250 IU per three adult doses of platelets.
Method of administration
For intramuscular use (preferably into the deltoid muscle).
D-GAM ® vials are for single use only.
In the case of haemorrhagic disorders, where intramuscular injections are contraindicated, Anti-D immunoglobulin may be administered subcutaneously. Careful manual pressure with a compress should be applied to the site after injection.
If large total doses (>5 mL) are required, it is advisable to administer them in divided doses at different sites.
4.3 Contraindications
Hypersensitivity to any of the components.
4.4 Special warnings and precautions for use
Do not administer this product intravenously (risk of shock).
In the case of post-partum use, the product is intended for maternal administration. It should not be given to the newborn infant.
The product is not intended for use in RhD positive individuals.
Patients should be observed for at least 20 minutes after administration.
If symptoms of allergic or anaphylactic type reactions occur, immediate discontinuation of the administration is required.
True hypersensitivity reactions are rare but allergic type responses to Anti-D immunoglobulin may occur. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. The treatment required depends on the nature and severity of the side effect. In case of shock, the current medical standards for shock treatment should be observed.
D-GAM ® contains a small quantity of IgA. Although anti-D immunoglobulin has been used successfully to treat selected IgA deficient individuals, the attending physician must weigh the benefit against the potential risks of hypersensitivity reactions. Individuals deficient in IgA have a potential for development of IgA antibodies and anaphylactic reactions after administration of blood components containing IgA.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) and for the non-enveloped hepatitis A and parvovirus B19 viruses.
In the interest of patients, it is recommended that, whenever possible, every time that D-GAM ® is administered to them, the name and batch number of the product is registered.
4.5 Interaction with other medicinal products and other forms of interaction
Active immunisation with live virus vaccines (e.g. measles, mumps or rubella) should be postponed until 3 months after the administration of Anti-D immunoglobulin, as the efficacy of the live virus vaccine may be impaired. If Anti-D immunoglobulin needs to be administered within 2-4 weeks of a live virus vaccination, then the efficacy of such a vaccination may be impaired.
After injection of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results in serological testing.
The results of blood typing and antibody testing, including the Coombs’ or antiglobulin test, are significantly affected by the administration of anti-D immunoglobulin.
4.6 Pregnancy and lactation
This medicinal product is used in pregnancy.
4.7 Effects on ability to drive and use machines
No effects on ability to drive and use machines have been observed.
4.8 Undesirable effects
Local pain and tenderness can be observed at the injection site; this can be prevented by dividing larger doses over several injection sites.
The following side effects are known to be associated with Anti-D (the incidence has not been quantified): Occasionally fever, malaise, headache, cutaneous reactions and chills occur. In rare cases: nausea, vomiting, hypotension, tachycardia and allergic or anaphylactic type reactions, including dyspnoea and shock, are reported, even when the patient has shown no hypersensitivity to previous administration.
For information on viral safety see 4.4.
4.9 Overdose
given RhD and receive parameters,
frequent or
No data are available on overdosage. RhD negative patients who are positive blood or other products containing RhD positive red blood cells anti-D immunoglobulin should be monitored clinically and by biological because of the risk of haemolytic reaction.
In other RhD negative individuals, overdosage should not lead to more more severe undesirable effects than the normal dose.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: immune sera and immunoglobulins: Anti-D (Rh) immunoglobulin. ATC code: J06B B01.
Anti-D immunoglobulin contains specific antibodies (IgG) against the RhD antigen of human erythrocytes.
5.2 Pharmacokinetic properties
Measurable levels of antibodies are obtained approximately 8 hours after intramuscular injection. Peak serum levels are usually achieved 2 to 4 days later.
The half-life in the circulation of individuals with normal IgG levels is 3 to 5 weeks.
IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.
5.3 Preclinical safety data
D-GAM ® is a preparation of human plasma proteins, so safety testing in animals is not particularly relevant to the safety of use in man. Acute toxicity studies in rat and mouse showed species specific reactions, which bear no relevance to administration in humans.
Repeated dose safety testing is impracticable due to the induction of and interference with antibodies to human protein. Clinical experience provides no sign of tumourigenic and mutagenic effects.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium chloride
Glycine
Sodium acetate trihydrate Sodium hydroxide
6.2
Incompatibilities
This medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
Stored at 2° - 8°C: 2 years.
Stored at 25 °C: 1 week.
6.4 Special precautions for storage
D-GAM ® should be stored in the original container at 2°C to 8°C. Storage for up to one week at ambient temperatures (25 °C) in the original container is not detrimental. DO NOT FREEZE.
The condition of date-expired, or incorrectly stored product cannot be guaranteed. Such product may be unsafe, and should not be used.
6.5 Nature and contents of container
Neutral borosilicate glass vial (Type I Ph.Eur.) with overseal consisting of a halobutyl rubber wad (Type I Ph.Eur.), clear lacquered aluminium skirt and flip-off polypropylene cap.
6.6 Special precautions for disposal
The product should be brought to room or body temperature before use.
The solution should be clear or slightly opalescent. Do not use solutions which are cloudy or have deposits.
Any unused product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Bio Products Laboratory Limited
Dagger Lane
Elstree
Hertfordshire
WD6 3BX
United Kingdom.
8 MARKETING AUTHORISATION NUMBER(S)
PL 08801/0049 - 1,500 IU and 2,500 IU dose sizes.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31 July 2000
10
DATE OF REVISION OF THE TEXT
07/11/2012